JPS59118707A - ビニフイブレ−トを有効成分とする医薬 - Google Patents
ビニフイブレ−トを有効成分とする医薬Info
- Publication number
- JPS59118707A JPS59118707A JP58237756A JP23775683A JPS59118707A JP S59118707 A JPS59118707 A JP S59118707A JP 58237756 A JP58237756 A JP 58237756A JP 23775683 A JP23775683 A JP 23775683A JP S59118707 A JPS59118707 A JP S59118707A
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- formula
- poor
- represented
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims description 17
- 229940079593 drug Drugs 0.000 title claims description 5
- BFYRHDVAEJIBON-UHFFFAOYSA-N binifibrate Chemical compound C=1C=CN=CC=1C(=O)OCC(COC(=O)C=1C=NC=CC=1)OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 BFYRHDVAEJIBON-UHFFFAOYSA-N 0.000 title description 2
- 229950004495 binifibrate Drugs 0.000 title description 2
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000004087 circulation Effects 0.000 claims description 4
- 230000004089 microcirculation Effects 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 210000004369 blood Anatomy 0.000 claims description 3
- 239000008280 blood Substances 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 208000000044 Amnesia Diseases 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000002193 Pain Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 230000003788 cerebral perfusion Effects 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 230000006984 memory degeneration Effects 0.000 claims description 2
- 208000023060 memory loss Diseases 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 230000001052 transient effect Effects 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 210000004720 cerebrum Anatomy 0.000 claims 1
- 230000035622 drinking Effects 0.000 claims 1
- 230000002093 peripheral effect Effects 0.000 claims 1
- 239000002994 raw material Substances 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- -1 trihydroxypropyl Chemical group 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N 2-propanol Substances CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 200000000007 Arterial disease Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- DLZVZOBLKBDRLS-UHFFFAOYSA-N (2-chlorophenyl) 2-methylpropaneperoxoate Chemical compound C(C(C)C)(=O)OOC1=C(C=CC=C1)Cl DLZVZOBLKBDRLS-UHFFFAOYSA-N 0.000 description 1
- IWSCLBQLWWXIAW-UHFFFAOYSA-N 3-hydroxypropyl 2-(4-chlorophenoxy)-2-methylpropanoate Chemical compound OCCCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 IWSCLBQLWWXIAW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000164466 Palaemon adspersus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000003782 Raynaud disease Diseases 0.000 description 1
- 208000012322 Raynaud phenomenon Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000879 anti-atherosclerotic effect Effects 0.000 description 1
- 230000001315 anti-hyperlipaemic effect Effects 0.000 description 1
- 150000008378 aryl ethers Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
- 229960001214 clofibrate Drugs 0.000 description 1
- TXCGAZHTZHNUAI-UHFFFAOYSA-N clofibric acid Chemical compound OC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 TXCGAZHTZHNUAI-UHFFFAOYSA-N 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- YLGXILFCIXHCMC-JHGZEJCSSA-N methyl cellulose Chemical compound COC1C(OC)C(OC)C(COC)O[C@H]1O[C@H]1C(OC)C(OC)C(OC)OC1COC YLGXILFCIXHCMC-JHGZEJCSSA-N 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- KFLRWGSAMLBHBV-UHFFFAOYSA-M sodium;pyridine-3-carboxylate Chemical compound [Na+].[O-]C(=O)C1=CC=CN=C1 KFLRWGSAMLBHBV-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT24965/82A IT1155447B (it) | 1982-12-23 | 1982-12-23 | Composizione farmaceutiche contenenti binifibrato e loro uso terapeutico |
| IT24965A/82 | 1982-12-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59118707A true JPS59118707A (ja) | 1984-07-09 |
| JPH0340011B2 JPH0340011B2 (OSRAM) | 1991-06-17 |
Family
ID=11215279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58237756A Granted JPS59118707A (ja) | 1982-12-23 | 1983-12-15 | ビニフイブレ−トを有効成分とする医薬 |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS59118707A (OSRAM) |
| DE (1) | DE3344891A1 (OSRAM) |
| IT (1) | IT1155447B (OSRAM) |
-
1982
- 1982-12-23 IT IT24965/82A patent/IT1155447B/it active
-
1983
- 1983-12-12 DE DE19833344891 patent/DE3344891A1/de active Granted
- 1983-12-15 JP JP58237756A patent/JPS59118707A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| DE3344891A1 (de) | 1984-06-28 |
| IT8224965A0 (it) | 1982-12-23 |
| IT8224965A1 (it) | 1984-06-23 |
| DE3344891C2 (OSRAM) | 1987-10-15 |
| JPH0340011B2 (OSRAM) | 1991-06-17 |
| IT1155447B (it) | 1987-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3700172A1 (de) | Wasserloesliche n-(methyl)-glucamin- und glucaminsalze, verfahren zu ihrer herstellung und diese enthaltende arzneimittel | |
| JPS62155240A (ja) | 治療用化合物 | |
| EA016904B1 (ru) | Новый холиновый сокристалл эпалрестата | |
| KR100422276B1 (ko) | 치환된카복실산형태의음이온성비마취성진통제의모르핀염및디아모르핀염,이들의제조방법,이들의용도및이들염을포함하는제제 | |
| RU2468015C2 (ru) | Полиморфные формы деферасирокса (icl670a) | |
| CN103864760A (zh) | 一种盐酸法舒地尔化合物 | |
| KR20230024976A (ko) | 인덴 화합물, 이의 약제학적 조성물, 및 이의 치료학적 적용 | |
| RU2105554C1 (ru) | N-(2,4,6-триметилфенилкарбамоилметил)-n-аллилморфолиний бромид, проявляющий противоишемическое и антиаритмическое действие при ишемической болезни сердца и способ его получения | |
| JPH03503162A (ja) | 化学療法における毒性特性の改良 | |
| KR20040051485A (ko) | 광활성 비사이클롤, 그 제조방법과 이를 함유하는 조성물및 이용 | |
| RU2124888C1 (ru) | Средство для коррекции патологических состояний, связанных с нарушением метаболических процессов | |
| CN1128999A (zh) | 杂环化合物 | |
| JP3782121B2 (ja) | 新規な血行促進のために使用する医薬 | |
| US2957805A (en) | Therapeutic compositions for oral and parenteral administration | |
| CN118026980B (zh) | 二氢三粒小麦黄酮及其制备方法和用途 | |
| JPS5910563A (ja) | α−（Ｎ−ピロリル）−フエニル酢酸誘導体およびその製造方法 | |
| JPS61126026A (ja) | イソキノリンスルホン酸アミドを有効成分とする抗癌剤 | |
| CA1337972C (en) | Agent for treating hyperuricemia | |
| RU2016571C1 (ru) | Средство для лечения гиперурикемии | |
| US2899358A (en) | Process | |
| CA1301776C (en) | Compound of choline, a process for its preparation and therapeutic composition containing it | |
| JPH01149723A (ja) | 骨芽細胞活性化剤 | |
| RU2201736C1 (ru) | Ушные капли бротинум | |
| JPS58140020A (ja) | 脂質代謝改善剤 | |
| JPH0340011B2 (OSRAM) |